SG-233

N/A

Report date: 2026/04/24 15:37:19

Base Information

Drug NameSG-233
Drug Alias NameAnti-CD22 CAR CD8 T-cell therapy (Sana Biotechnology)In vivo engineered anti-CD22 CAR T-cell therapy (Sana Biotechnology)SG-233
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > In vivo CAR-T therapyCell and gene therapy > Cell therapy > In vivo cell therapy > In vivo CAR-T therapy
Mechanisms of ActionCD22 modulators
TargetsCD22
Therapy Area/IndicationsLymphoma, Non-HodgkinPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Lymphocytic, Chronic, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSana Biotechnology Inc
China Registration ClassN/A

Develop Information

Active CompaniesSana Biotechnology Inc
Inactive CompaniesN/A
Active IndicationsLymphoma, Non-HodgkinPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Lymphocytic, Chronic, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A